cabozantinib,atezolizumab
exelixis,roche
['cabozantinib', 'cosmic-021']
cosmic-021 study: cabozantinib + atezo (n=81) or cabozantinib (n=31) in pts previously treated with io--&gt; orr 19% &amp; 6% dcr 80% &amp; 65% pfs 4.5 mo &amp; 3.4 mo md os 13.8 &amp; 9.4 months #asco22 #lcscm 
Assistant Prof | Thoracic Oncology & Phase-I  @karmanoscancer | Previously @MayoCancerCare @gundersenhealth @JeffHealthAb @bpkihsofficial | Views/Tweets my own